Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy

Table 4 Survival of patients according to neutrophil-lymphocyte ratio (NLR) before both neoadjuvant chemotherapy and surgery

NLR changed by chemotherapy^a			Number	PFS		OS
NLR changed by chemotherapy^a			Number	Median survival, months	P value	Median survival, months	P value
NLR >2.5	→	NLR >2.5	13	10		16
NLR ≤2.5	→	NLR ≤2.5	15	49	<0.001	42	0.015
NLR >2.5	→	NLR ≤2.5	11	35		60
NLR ≤2.5	→	NLR ≤2.5	15	49	0.648	42	0.869
NLR >2.5	→	NLR ≤2.5	11	35		60
NLR >2.5	→	NLR >2.5	13	10	0.003	16	0.042

ISSN: 1477-7819